Protein / target

Enoyl-[acyl-carrier-protein] reductase [NADH]

inhAP9WGR1Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)Swiss-Prot
UniProt: P9WGR1NCBI Gene: 45425463
30
Clinical trials
2
Drugs targeting

Protein at a glance

Biological role

Enoyl-[acyl-carrier-protein] reductase (NADH) activity

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Enoyl-ACP reductase of the type II fatty acid syntase (FAS-II) system, which is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls (PubMed:25227413). Catalyzes the NADH-dependent reduction of the double bond of 2-trans-enoyl-[acyl-carrier protein], an essential step in the fatty acid elongation cycle of the FAS-II pathway (PubMed:7599116). Shows preference for long-chain fatty acyl thioester substrates (>C16), and can also use 2-trans-enoyl-CoAs as alternative substrates (PubMed:7599116). The mycobacterial FAS-II system utilizes the products of the FAS-I system as primers to extend fatty acyl chain lengths up to C56, forming the meromycolate chain that serves as the precursor for final mycolic acids (PubMed:25227413)

Domains and Gene Ontology detail (9)

Gene Ontology

  • Cpeptidoglycan-based cell wall
  • Cplasma membrane
  • Fenoyl-[acyl-carrier-protein] reductase (NADH) activity
  • Ffatty acid binding
  • FNAD+ binding
  • Ftrans-2-enoyl-CoA reductase (NADH) activity
  • Pfatty acid elongation
  • Pmycolic acid biosynthetic process
  • Presponse to antibiotic

269 aa · 29 kDa

Drugs targeting this protein

2

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Isoniazid
Narrow target profileInhibitor

Enoyl-[acyl-carrier-protein] reductase inhibitor

Direct interaction with this protein · Only this protein recorded as a target

Ethionamide
Narrow target profileInhibitor

Enoyl-[acyl-carrier-protein] reductase inhibitor

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary TuberculosisPHASE2

RECRUITING · via Isoniazid · NCT06114628

The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis PatientsPHASE4

UNKNOWN · via Isoniazid · NCT02477852

A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifampin-Based Tuberculosis Treatment Versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifabutin-Based Tuberculosis Treatment With or Without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIVPHASE2

TERMINATED · via Isoniazid · NCT01601626

Impact of LTBI Treatment on Glucose Tolerance and Chronic InflammationPHASE4

COMPLETED · via Isoniazid · NCT04830462

Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical TrialPHASE2

NOT_YET_RECRUITING · via Isoniazid · NCT06917495

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary TuberculosisPHASE2

COMPLETED · via Ethionamide · NCT05473195

Show remaining trials (24)
Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority TrialPHASE4

UNKNOWN · via Isoniazid · NCT02901288

Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional ApproachPHASE4

UNKNOWN · via Isoniazid · NCT01875952

The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV InfectionPHASE3

COMPLETED · via Isoniazid · NCT00001033

The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation (PTTKT):Protocol for an Open-label, Prospective, Randomized, 3-arm, Controlled TrialNA

UNKNOWN · via Isoniazid · NCT05249699

Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis PreventionPHASE1

COMPLETED · via Isoniazid · NCT05413551

Rosuvastatin Evaluation as a Tuberculosis Treatment AdjunctPHASE2

UNKNOWN · via Isoniazid · NCT04504851

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected IndividualsPHASE2

TERMINATED · via Isoniazid · NCT04272242

A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary TuberculosisPHASE2

COMPLETED · via Isoniazid · NCT01785186

A Ultrashort Regimen for Drug-susceptible Pulmonary Tuberculosis in Elderly Patients: A Multicenter Randomized Controlled TrialPHASE3

NOT_YET_RECRUITING · via Isoniazid · NCT07076225

Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis Based on N-Acetyltransferase Type 2 GenotypingNA

UNKNOWN · via Isoniazid · NCT03787940

A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of RiskPHASE2/PHASE3

UNKNOWN · via Isoniazid · NCT02735590

A Multiple-arm, Multiple-stage (MAMS), Phase 2B/C, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary TuberculosisPHASE2

RECRUITING · via Isoniazid · NCT05807399

TBTC Study 27/28 PK: Pharmacokinetic Issues in the Use of Moxifloxacin for Treatment of TuberculosisPHASE2

COMPLETED · via Isoniazid · NCT00164463

Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible TuberculosisPHASE2

NOT_YET_RECRUITING · via Isoniazid · NCT07129629

A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence SettingsPHASE4

COMPLETED · via Isoniazid · NCT01494038

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2PHASE4

COMPLETED · via Isoniazid · NCT03278483

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based RegimenNA

UNKNOWN · via Isoniazid · NCT00018083

A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TBPHASE2

UNKNOWN · via Isoniazid · NCT05124678

Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)PHASE4

COMPLETED · via Isoniazid · NCT01380080

Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection SurgeryPHASE1

COMPLETED · via Isoniazid · NCT00816426

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)PHASE2/PHASE3

ACTIVE_NOT_RECRUITING · via Isoniazid · NCT05766267

A Phase 2C Trial of Stratified Patient-Centered Treatment Regimens for Active TBPHASE2

NOT_YET_RECRUITING · via Isoniazid · NCT07595042

An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary TuberculosisPHASE3

COMPLETED · via Isoniazid · NCT02581527

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based RegimenPHASE2/PHASE3

COMPLETED · via Isoniazid · NCT00023348

ClinicalTrials.gov via the drug-target graph.

What's happening now

6

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. New publication2024-03-28
    Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

    BMJ global health · 2024 · 4 citations · Europe PMC · via Isoniazid

  2. New publication2022-12-01
    Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022 · 3 citations · Europe PMC · via Isoniazid

  3. New publication2013-03-07
    Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.

    Infectious diseases in obstetrics and gynecology · 2013 · 36 citations · Europe PMC · via Isoniazid

  4. New publication2013-02-01
    Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2013 · 5 citations · Europe PMC · via Isoniazid

  5. New publication2011-04-25
    Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana.

    PloS one · 2011 · 40 citations · Europe PMC · via Isoniazid

  6. New publication2011-04-12
    6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

    Lancet (London, England) · 2011 · 252 citations · Europe PMC · via Isoniazid

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.